Arundic acid (ONO-2506) inhibits secondary injury and improves motor function in rats with spinal cord injury

Mitsuru Hanada, Ryuichi Shinjo, Michihito Miyagi, Tatsuya Yasuda, Koji Tsutsumi, Yuki Sugiura, Shiro Imagama, Naoki Ishiguro, Yukihiro Matsuyama

Research output: Contribution to journalArticlepeer-review

15 Citations (Scopus)


Background Arundic acid (ONO-2506) inhibits the production and release of S100 protein from astrocytes. While numerous studies have assessed the effect of ONO-2506 in the diseased brain, to the best of our knowledge, no study has examined the effect of ONO-2506 in spinal cord injury (SCI). In this study, we administered ONO-2506 to rats with SCI in order to evaluate its effectiveness in improving motor function and protecting against histological injury. Methods All rats underwent laminectomy with SCI at the 10th thoracic vertebra. Rats were divided into 3 groups that received different concentrations of ONO-2506 as follows: 10 mg/kg (Group I) and 20 mg/kg (Group II). The third group (control group) was administered only saline. ONO-2506 or saline was administered by intravenous injection for a week after SCI. Recovery of motor function was assessed by determining the Basso, Beattie, and Bresnahan (BBB) scores and using the %grip test. Using immunohistochemistry, S100 protein and glial fibrillary acidic protein expression was assessed at week 12 post SCI. Results The BBB score of Group II was significantly better than that of the control group. At week 12 post SCI, the %grip was 43.0% in Group II and 20.3% in Group I. The score for the %grip test was greater for Group II than for the control group (7.0%); thus, motor function improvement appeared to be dose dependent. Regarding immunostaining evaluation, S100 protein staining was lower in Group II compared to the control group, and the astrocytic morphology resembled that of normal spinal cord sections. The SCI lesion expanded from the injured site to both proximal and distal sites in the control group and in Group I. However, despite the presence of cavitation, secondary expansion of the SCI lesion was prevented in Group II as a result of inhibition of S100 protein. Conclusions Administration of ONO-2506 (20 mg/kg) improves motor function and inhibits expansion of secondary injury in SCI rats.

Original languageEnglish
Pages (from-to)186-192
Number of pages7
JournalJournal of the Neurological Sciences
Issue number1-2
Publication statusPublished - 2014 Feb 15
Externally publishedYes


  • Arundic acid
  • Astrocyte
  • Motor function
  • S100 protein
  • Secondary injury
  • Spinal cord injury

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Arundic acid (ONO-2506) inhibits secondary injury and improves motor function in rats with spinal cord injury'. Together they form a unique fingerprint.

Cite this